Canada: Use It Or...... Else: Patent Non-Use As Abuse Of Dominant Market Position

In a matter of a first impression under the Canadian Competition Act, on May 13, 2014 the Competition Bureau released a Position Statement1 regarding what it refers to as "product hopping" or "product switching". That is conduct designed to switch demand from one of a firm's patent protected products to another, with the goal of making generic entry more difficult. This is the first time that the Bureau has conducted a formal inquiry into product hopping, although the conduct has been subject to US and European competition scrutiny.2 In the particular Canadian case, however, the Bureau closed its inquiry under the abuse of dominant market position provisions of the Act without taking action, because it found that the product had only been withdrawn from the market for a limited period of time, such that no injury occurred.

Alcon Canada Inc. ("Alcon") was a supplier of the patented anti-allergy drug Patanol. One of the two patents protecting Patanol was set to expire in the Fall of 2012 and generic entry appeared likely to occur shortly thereafter. As a result, the Bureau alleged that Alcon began restricting the stock of Patanol available in the marketplace from July 2012. A short time before that it had introduced a new drug with much longer patent protection, Pataday. Pataday is indicated to address the same allergy concerns as Patanol, although it is a longer lasting formulation. Pataday's sales were increasing but were much smaller than those of Patanol until September 2012, when Patanol was no longer available in the marketplace. Sales of Pataday then replaced the vast majority of the sales of Patanol.

The Bureau's concern was that withdrawal of Patanol was designed to achieve product switching or product hopping. To become established in the marketplace, generic drugs generally depend on substitution of the generic drug for the prescribed brand name drugs by pharmacists. That is, if two drugs – one brand name and one generic – are chemically equivalent, pharmacists can (and under many drug plans are required to) substitute the less expense generic for the more expensive brand name drug. However, insofar as prescriptions are no longer written for the original brand name drug because it has been withdrawn from the marketplace by the manufacturer, and are instead written for a chemically different replacement drug, for which – because of extended patent protection – there is no generic substitute, the pharmacist cannot substitute generic version of the withdrawn brand name drug on prescriptions written for the newly introduced and chemically different brand name drug. This will deprive the generic drug of significant sales, and may discourage generic manufacturers from introducing the drug into the marketplace at all.

In the case in question, as noted the Bureau closed its inquiry in March 2014. It found that while Patanol had been withdrawn in the Summer of 2012 it was reintroduced into the marketplace relatively soon after the Bureau launched its inquiry. By May of 2013, which was the beginning of the allergy season during which demand was high for the drug, Patanol's sales were back where they had been prior to the withdrawal. Further, the Bureau noted that competitors subsequently entered the marketplace with generic versions of Patanol and captured a significant market share.

This is the first instance – at least first publicly known instance – of the Bureau pursuing product hopping as an anti-competitive act under the abuse of dominance provisions of the Competition Act. The Bureau notes in its Position Statement that life cycle management strategies in the pharmaceutical sector are not inherently anti-competitive, and may bring significant advancements in health care. Nevertheless, there is clearly a concern that product hopping may be anti-competitive. The question is, however, whether the Bureau's approach to enforcement with respect to product hopping is consistent with intellectual property laws, with the Competition Act, and with existing jurisprudence related to the interface between competition and intellectual property laws.

Pursuant to the Bureau's existing Intellectual Property Enforcement Guidelines3 the "mere exercise" of intellectual property rights – including refusing to supply someone with intellectual property rights – will not, in the Bureau's view, constitute an infringement of the Competition Act – except possibly under the special remedies provisions in Section 32 which have been employed only very very rarely.

The mere exercise of an IP right is not cause for concern under the general provisions of the Competition Act. The Bureau defines the mere exercise of an IP right as the exercise of the owner's right to unilaterally exclude others from using the IP. The Bureau views an IP owner's use or non-use (emphasis added) of the IP also as being the mere exercise.4

However, in April 2014 the Bureau published revised Draft update of Intellectual Property Enforcement Guidelines5 – essentially updating the existing Guidelines given statutory changes in the interim. Virtually the only substantive change to those Guidelines was with respect to non-use of intellectual property. Under the new Draft Guidelines, refusal to use intellectual property could be challenged under the abuse of dominance provision. In the above quoted provisions the words "or non-use" were struck from the paragraph of the revised Draft Guidelines.6

Whether the Bureau's view in its new Draft Guidelines – that non-use of intellectual property, in particular by product hopping, can be challenged under the abuse of dominance provision of the Competition Act – is an open question. Section 79(5) of the Competition Act provides:

79(5). For the purpose of this section, an act engaged in pursuant only to the exercise of any right or enjoyment of any interest derived under the Copyright Act, Industrial Design Act, Integrated Circuit Topography Act, Patent Act, Trade-marks Act or any other Act of Parliament pertaining to intellectual or industrial property is not an anti-competitive act.

In the Tele-Direct7 case, dealing with refusal to allow use of trade-marks, the Tribunal stated:

The respondents' refusal to license their trade-marks falls squarely within their prerogative. Inherent in the very nature of the right to license a trade-mark is the right for the owner of the trade-mark to determine whether or not, and to whom, to grant a licence; selectivity in licensing is fundamental to the rationale behind protecting trade-marks. The respondents' trade-marks are valuable assets and represent considerable goodwill in the marketplace. The decision to license a trade-mark -- essentially, to share the goodwill vesting in the asset -- is a right which rests entirely with the owner of the mark. The refusal to license a trade-mark is distinguishable from a situation where anti-competitive provisions are attached to a trade-mark licence.8

In the Warner Music9 case dealing with refusal to supply copyright materials, the Tribunal stated:

The Copyright Act is similar to the Trade-marks Act, in that it allows the trade-mark owner to refuse to license and it places no limit on the sole and exclusive right to license.10

Further, it is worth noting that, prior to 1993 the Patent Act contained a provision allowing the invalidation of a product for "non-working".11

65(2). The exclusive rights under a patent shall be deemed to have been abused in any of the following circumstances: (a) if the patented invention (being one capable of being worked within Canada) is not being

worked within Canada on a commercial scale, and no satisfactory reason can be given.

In 1993 that provision was repealed.12

Given all of the foregoing, it is difficult to understand how the mere refusal to supply a patent protected product could constitute an abuse of dominant market position. The case against Alcon did not proceed, but if a similar case is pursued in the future these issues will, no doubt, be tested.


1 Competition Bureau, Competition Bureau Statement Regarding the Inquiry into Alleged Anti-Competitive Conduct by Alcon Canada Inc. (May 13, 2014), available online:

2 Mylan Pharmaceuticals, Inc., et al. v. Warner Chilcott Public Limited Company, et al., Civ. No. 12-3824 (E.D.Pa.); Commission fines AstraZeneca €60 million for misusing patent system to delay market entry of competing generic drugs (June 15, 2005), available online:

3 Competition Bureau, Intellectual Property Enforcement Guidelines (September 2000), available online:

4 Ibid., para. 4.2.1.

5 Competition Bureau, Draft update of Intellectual Property Enforcement Guidelines (April 2, 2014), available online:

6 Ibid., para 4.2.1.

7 Director of Investigation and Research v. Tele-Direct (Publications) Inc., CT-1994-003 (Comp. Trib.).

8 Ibid., page 40.

9 Director of Investigation and Research v. Warner Music Canada Ltd., CT-1997-003 (Comp. Trib.).

10 Ibid., page 17. See also Harris v. Glaxosmithkline Inc. 106 O.R. (3d) 661.

11 Patent Act, RSC 1985, c P-4, s. 65(2)(a).

12 Patent Act Amendment Act, S.C. 1993, c.2, s. 5.

The foregoing provides only an overview and does not constitute legal advice. Readers are cautioned against making any decisions based on this material alone. Rather, specific legal advice should be obtained.

© McMillan LLP 2014

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

James B. Musgrove
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.